A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts by Garcia-Manero, Guillermo et al.
OPEN
ORIGINAL ARTICLE
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azacitidine in adults with MDS, CMML or AML with
⩽ 30% blasts
G Garcia-Manero1, MA Sekeres2, M Egyed3, M Breccia4, C Graux5, JD Cavenagh6, H Salman7, A Illes8, P Fenaux9, DJ DeAngelo10,
R Stauder11, K Yee12, N Zhu13, J-H Lee14, D Valcarcel15, A MacWhannell16, Z Borbenyi17, L Gazi18, S Acharyya19, S Ide20, M Marker21
and OG Ottmann22
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with
higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is o2 years, novel agents are needed to
improve outcomes. This phase 1b/2b trial (n= 113) was designed to determine the maximum tolerated dose (MTD) or
recommended phase 2 dose (RP2D) of panobinostat (PAN)+AZA (phase 1b) and evaluate the early efﬁcacy and safety of PAN+AZA
vs AZA monotherapy (phase 2b) in patients with higher-risk MDS, chronic myelomonocytic leukemia or oligoblastic acute myeloid
leukemia with o30% blasts. The MTD was not reached; the RP2D was PAN 30 mg plus AZA 75 mg/m2. More patients receiving PAN
+AZA achieved a composite complete response ([CR)+morphologic CR with incomplete blood count+bone marrow CR (27.5% (95%
CI, 14.6–43.9%)) vs AZA (14.3% (5.4–28.5%)). However, no signiﬁcant difference was observed in the 1-year OS rate (PAN+AZA, 60%
(50–80%); AZA, 70% (50–80%)) or time to progression (PAN+AZA, 70% (40–90%); AZA, 70% (40–80%)). More grade 3/4 adverse
events (97.4 vs 81.0%) and on-treatment deaths (13.2 vs 4.8%) occurred with PAN+AZA. Further dose or schedule optimization may
improve the risk/beneﬁt proﬁle of this regimen.
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INTRODUCTION
Myelodysplastic syndromes (MDS) represent a heterogeneous
group of myeloid disorders characterized by severe cytopenias
and dysplasias in one or more myeloid lineages. Subclassiﬁcation
of MDS according to several prognostic systems identiﬁes patients
at substantial risk for transformation to acute myeloid leukemia
(AML), which is generally refractory to standard treatment.1 MDS
remains incurable without stem cell transplant, but eligibility is
restricted by the advanced age of patients.2 Azacitidine (AZA), the
current standard frontline therapy for higher-risk MDS, signiﬁ-
cantly prolonged overall survival (OS) in these patients and has
shown clinical beneﬁt in those with AML.3–5 However, response
rates with AZA therapy are generally o30%6,7 and of limited
durability, with all nontransplanted patients eventually progres-
sing or dying, highlighting the signiﬁcant need for novel agents
that improve both response rates and duration of responses.
Panobinostat (PAN) is a potent oral pan-deacetylase inhibitor
(DACi) approved in the United States, the European Union, Japan
and Switzerland for patients with multiple myeloma.8 PAN
modulates the acetylation of histone proteins and protein
chaperones in malignant cells. The epigenetic regulation by PAN
is primarily mediated through the inhibition of class I histone
deacetylase (HDAC) enzymes, leading to increased histone
acetylation, relaxation of chromatin and alteration of gene
expression, including that of tumor suppressor genes.9 In a phase
1a/2 study of PAN in patients with advanced hematologic
malignancies, a manageable safety proﬁle was established, but
only modest efﬁcacy was demonstrated in patients with AML or
MDS.10
In recent years, the involvement of epigenetic processes in the
pathogenesis of MDS and the transformation to AML has been
extensively studied. Several preclinical and clinical studies have
demonstrated hypermethylation of CpG islands at the promoter
regions of a number of genes.11 Additionally, epigenetic silencing
of tumor suppressor genes in MDS, potentially mediated through
dysregulated histone acetylation, has been associated with
transformation to AML and poor prognosis.12 That both AZA
and DACi modulate aberrant gene expression by different
mechanisms suggests that they may act synergistically in MDS
and AML. Preclinically, synergy of PAN and demethylating agents
has been established in primary AML cells, with the combination
of PAN and decitabine leading to a signiﬁcant reduction in AML
cell viability compared with either agent alone.13 A limited
number of clinical trials investigating the combination of DACi
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and demethylating agents have been fully reported. Findings from
early-phase clinical trials of AZA plus the DACi valproic acid with or
without all-trans retinoic acid have shown promising response
rates.14,15 As PAN is among the most potent DACi in clinical
development,16 we hypothesized that the addition of PAN could
improve the clinical beneﬁt of AZA monotherapy. On the basis of
these data, the current phase 1b/2b study was designed to
determine the maximum tolerated dose (MTD) or recommended
phase 2 dose (RP2D), and the early efﬁcacy and safety, of PAN in
combination with AZA in patients with high-risk MDS, oligoblastic
AML or chronic myelomonocytic leukemia (CMML).
PATIENTS AND METHODS
Patients
Adult patients (aged ⩾ 18 years) with International Prognostic Scoring
System (IPSS) intermediate-2- or high-risk MDS, CMML or AML with
multilineage dysplasia and ⩽ 30% bone marrow blasts who were not
planning to undergo hematopoietic stem cell transplant were enrolled. Key
inclusion criteria were an Eastern Cooperative Oncology Group perfor-
mance status (ECOG PS) ⩽ 2 and adequate hepatic and renal function.
Patients with therapy-related MDS or AML, relapsed/refractory AML, clinical
symptoms of central nervous system leukemia, or impaired cardiac
function were excluded. Additionally, patients who had received prior
treatment with a DACi, AZA or decitabine, or who were currently receiving
a drug known to prolong the QT interval that could not be terminated,
were not eligible. The study protocol was reviewed by the independent
ethics committee or institutional review board at each center, and written
informed consent was obtained from each patient prior to screening.
Study design
This was an open-label, multicenter, international, phase 1b/2b study. In
phase 1b, the primary objective was determination of the MTD or RP2D of
PAN in combination with AZA (Figure 1). Other objectives included early
analyses of the regimen’s safety and efﬁcacy. Patients were enrolled in
escalating dose cohorts consisting of ⩾ 3 patients each. The starting dose
of PAN was 20 mg administered orally on days 3, 5, 8, 10, 12 and 15 in
combination with AZA 75 mg/m2 administered on days 1 to 7 in 4-week
cycles. Successive cohorts received escalating doses of PAN until
determination of MTD or RP2D. AZA was administered according to its
label. Dose reductions or interruptions of PAN and AZA were permitted,
but the PAN dose was not to decrease below 10 mg, and no cycle could be
extended longer than 42 days. Patients were evaluated for dose-limiting
toxicities (DLTs), and dose escalation was guided by an adaptive Bayesian
logistic regression model (BLRM). The MTD could not be declared until ⩾ 9
patients were evaluated at that dose level.
Upon determination of the MTD or RP2D deﬁned in phase 1b, an
additional 80 patients were to be enrolled in the phase 2b portion and
randomly assigned in the ratio 1:1 following Interactive Response
Technology procedures to receive either the MTD/RP2D of PAN plus AZA
(PAN+AZA) or single-agent AZA on a treatment schedule identical to that
from phase 1b. Because the study population consisted of patients with
three different indications (MDS, CMML and AML) with varying response
assessment criteria, a composite end point that could be used across all
three indications to obtain an overall response assessment was devised.
This composite end point was named 'composite complete response'
(composite CR) and pooled together 'complete response/complete
remission' (CR; applicable to both AML and MDS/CMML), 'morphologic
CR with incomplete blood count' (CRi; applicable to AML) and 'bone
marrow CR' (BM-CR; applicable to MDS/CMML). The primary objective of
phase 2b was to assess the early efﬁcacy of PAN at the MTD/RP2D in
combination with AZA vs AZA alone through the assessment of composite
CR. Secondary objectives included efﬁcacy assessment of clinical responses
other than composite CR, 1-year survival, time to progression and
assessment of safety in comparison with single-agent AZA.17,18 Patients
in both phases were allowed to continue study treatment until disease
progression, unacceptable toxicity or withdrawal of consent.
Safety and efﬁcacy assessments
Patients were monitored for safety throughout the trial and up to 28 days
after the last dose of study treatment. Adverse events (AEs) were assessed
according to the Common Terminology Criteria for Adverse Events version
3.0. Safety evaluations included monitoring of hematology, blood
chemistry and urine, and regular assessment of vital signs, physical
condition, body weight, ECOG PS and cardiac monitoring.
Assessment of response was made per the investigator, based on
standardized criteria proposed by the international working groups for
AML17 and MDS/CMML.18 Response during study treatment was evaluated
via blood and bone marrow assessment. Bone marrow aspiration and/or
core biopsy was obtained within 5 days of the planned end of even-
numbered cycles, at the end of treatment visit and at the discretion of the
investigator. Peripheral blood assessments were performed within 5 days
of bone marrow aspiration/biopsy, unless not clinically feasible.
Bone marrow aspirate samples were collected at screening from patients
in phase 2b and sent for next-generation sequencing analysis (NGS;
Genoptix, Carlsbad, CA, USA). Genomic DNA was isolated from the
samples, and the coding regions of 24 genes (Supplementary Table 1)
were ampliﬁed by polymerase chain reaction and sequenced using NGS
technology (MiSeq system; Illumina, Inc, San Diego, CA, USA). Somatic
mutations consistent with AML, MDS or myeloproliferative neoplasms were
identiﬁed. This study is registered at http://clinicaltrials.gov as
NCT00946647.
Statistical analysis
An adaptive BLRM and dose-escalation criteria similar to that proposed by
Babb, Rogatko and Zacks, including the escalation with overdose control
principle,19 was used to guide dose escalation in phase 1b. The study was
Phase 1b—dose escalation
• IPSS Int-2 or high-
risk MDS, CMML, 
or AML with 
multilineage
dysplasia and  30% 
bone marrow blasts
• ≥ 18 years of age
• ECOG PS ≤ 2
• Adequate hepatic 
and renal function
75 mg/m  AZA D1-7
In combination with escalating
dose cohorts of PAN
D3, 5, 8, 10, 12 & 15
20 mg PAN (n = 6)
30 mg PAN (n = 18)
40 mg PAN (n = 7)
Randomization (1:1) 
N = 82 
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determine MTD or RP2D Inclusion criteria
Phase 2b
primary objective: 
assess early efficacy of 
PAN+AZA vs AZA alone
PAN + AZA (n = 40)
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+
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Figure 1. Study design. In phase 1b, patients received escalating doses of PAN in combination with AZA. In phase 2b, patients were
randomized to receive treatment with either the RP2D of PAN+AZA or single-agent AZA. AML, acute myeloid leukemia; AZA, azacitidine;
CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IPSS Int-2, International
Prognostic Scoring System intermediate 2; MDS, myelodysplastic syndrome; MTD, maximum tolerated dose; PAN, panobinostat; RP2D,
recommended phase 2 dose.
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not designed for hypothesis testing of comparisons between the
treatment arms. Point estimates and 95% exact binomial CIs20 were
computed to provide descriptive summaries of response rates. The 1-year
survival probabilities were estimated from the Kaplan−Meier curve. All
analyses were done using SAS software (version 9.3) and R software
(version 2.13).
RESULTS
Patients and disposition
A total of 113 patients were enrolled in the study and received
treatment starting 4 December 2009; data cutoff for this analysis
was 30 April 2014, corresponding to the time point at which the
last patient enrolled in the phase 2 part of the study should have
completed 12 cycles of treatment. In phase 1b, 31 patients
(median age, 69 years; Table 1) received PAN in dosing cohorts of
20 mg (n= 6), 30 mg (n= 18) and 40 mg (n= 7). At the time of data
cutoff, four patients remained on treatment (30 mg (n= 3); 40 mg
(n= 1)). Patients in phase 1b had diagnoses of MDS (n= 16), CMML
(n= 4) and AML (n= 11). The majority of patients with MDS were
previously untreated (81.3%), categorized as IPSS intermediate-2
(87.5%) or high risk (12.5%) at study entry, and had favorable
cytogenetics per IPSS (62.5%); 12.5% had unfavorable cytoge-
netics. Among the patients with CMML, 75% were previously
untreated. All patients with AML were previously untreated for
AML; 72.7% had prior MDS that transformed to AML, and 1 of
these patients received prior treatment with lenalidomide for
MDS. The majority of patients with AML (54.5%) had unfavorable
cytogenetics; the remaining 45.5% had intermediate cytogenetic
risk. The median time from initial diagnosis to study entry for
patients with MDS, CMML and AML was 1.3 months (range,
0.5–37.9 months), 1.8 months (range, 0.8–3.2 months) and
0.7 months (range, 0.2–2.5 months), respectively. Most patients
had an initial ECOG PS of either 0 (41.9%) or 1 (48.4%).
Demographics and baseline characteristics for patients in phase
1b are presented in Table 1.
Eighty-two patients (median age, 71 years) were enrolled in
phase 2b and randomized to receive treatment with PAN+AZA
(n= 40) or AZA (n= 42). At the time of data cutoff, 13 patients
remained on treatment (PAN+AZA (n= 7); AZA (n= 6)). Of the 82
phase 2b patients, 47 (57.3%), 13 (15.9%) and 22 (26.8%) had a
diagnosis of MDS, CMML and AML, respectively. The majority of
patients with MDS were previously untreated (89.4%), and 44.7%
had unfavorable cytogenetics (patients with favorable and
intermediate cytogenetics accounted for 27.7% each). Patients
with CMML were primarily untreated (84.6%), and nearly all
patients with AML (95.5%) were previously untreated for AML.
Most patients with AML had multilineage dysplasia with 21–30%
bone marrow blasts (95.5%), with 77.3% of these patients having
prior MDS that transformed to AML and 81.8% having inter-
mediate- or high-risk cytogenetics. ECOG PS at baseline was
primarily 0 (41.5%) or 1 (52.4%). A comparison of demographics
and baseline characteristics between treatment arms is presented
in Table 2.
Determination of MTD or RP2D
Of the 31 patients enrolled in phase 1b, 26 were evaluable for
MTD determination (20 mg, n= 5; 30 mg, n= 14; 40 mg, n= 7). Six
DLTs were observed. In the 20-mg cohort, one patient experi-
enced a DLT of septic shock. Three patients in the 30-mg cohort
experienced DLTs, which included atrial ﬁbrillation and syncope,
dehydration and fatigue, and colitis. In the 40-mg cohort, two
patients experienced DLTs of grade 3 nausea and vomiting and
grade 3 hyperbilirubinemia. The MTD for PAN was not reached.
Although DLTs were rare, two patients (29%) required at least one
PAN dose reduction and one patient (14%) required at least
one AZA dose reduction. Based on the BLRM and safety ﬁndings,
the 30- mg dose was selected as the RP2D.
Safety
During phase 1b dose escalation, nearly all patients (96.8%)
reported ⩾ 1 grade 3/4 AE, regardless of study drug relationship.
Table 1. Demographics and baseline characteristics of patients enrolled in the phase 1b portion by initial dose group of PAN
PAN+AZA 20 mg (n= 6) PAN+AZA 30 mg (n= 18) PAN+AZA 40 mg (n= 7) All patients (N= 31)
Median age (range), years 70 (60–80) 70.5 (57–81) 69 (34–79) 69 (34–81)
Female/male, % 33.3/66.7 55.6/44.4 57.1/42.9 51.6/48.4
Disease, n (%)
MDS 5 (83.3) 10 (55.6) 1 (14.3) 16 (51.6)
CMML 1 (16.7) 2 (11.1) 1 (14.3) 4 (12.9)
AML 0 6 (33.3) 5 (71.4) 11 (35.5)
ECOG PS, n (%)
0 2 (33.3) 10 (55.6) 1 (14.3) 13 (41.9)
1 3 (50.0) 7 (38.9) 5 (71.4) 15 (48.4)
2 1 (16.7) 1 (5.6) 1 (14.3) 3 (9.7)
Abbreviations: AML, acute myeloid leukemia; AZA, azacitidine; CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group
performance status; MDS, myelodysplastic syndromes; PAN, panobinostat.
Table 2. Demographics and baseline characteristics of patients
enrolled in the phase 2b portion by treatment group
PAN+AZA
(n= 40)
AZA (n= 42) All patients
(N=82)
Age, median
(range), years
68 (44–81) 72 (42–85) 71 (42–85)
Female/male, % 27.5/72.5 40.5/59.5 34.1/65.9
Disease, n (%)
MDS 25 (62.5) 22 (52.4) 47 (57.3)
CMML 6 (15.0) 7 (16.7) 13 (15.9)
AML 9 (22.5) 13 (31.0) 22 (26.8)
ECOG PS, n (%)
0 14 (35.0) 20 (47.6) 34 (41.5)
1 25 (62.5) 18 (42.9) 43 (52.4)
2 1 (2.5) 4 (9.5) 5 (6.1)
Abbreviations: AML, acute myeloid leukemia; AZA, azacitidine; CMML,
chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncol-
ogy Group performance status; MDS, myelodysplastic syndromes; PAN,
panobinostat.
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The most common grade 3/4 AEs (in ⩾ 20% of patients) were
primarily hematologic, including thrombocytopenia (54.8%),
neutropenia (41.9%), anemia (32.3%) and febrile neutropenia
(29.0%; Table 3). Three patients (9.7%) died while on treatment (or
⩽ 28 days after the end of treatment) from underlying malignancy
(n= 2) and renal insufﬁciency not attributed to study treatment
(n= 1).
In phase 2b, a total of 80 randomized patients (38, PAN+AZA;
42, AZA) received at least one dose of study treatment and were
included in the safety set. The median duration of treatment with
PAN was 20.5 weeks (5.1 cycles; range, 0.03–23.3 cycles), and the
median duration of treatment with AZA was 23.4 weeks (5.9
cycles; range, 0.1–23.4 cycles) in the PAN+AZA arm vs 16.9 weeks
(4.2 cycles; range, 0.03–23.6 cycles) in the AZA arm. A summary of
frequent AEs by treatment group in phase 2b is presented in
Table 4. A greater proportion of patients in the PAN+AZA arm
experienced ⩾ 1 grade 3/4 AE compared with the AZA arm (97.4 vs
81.0%). The most common grade 3/4 AEs with higher incidence in
the PAN+AZA arm than the AZA arm were thrombocytopenia
(55.3 vs 19.0%), febrile neutropenia (31.6 vs 19.0%) and anemia
(21.1 vs 11.9%). A slightly higher proportion of patients in the PAN
+AZA arm vs the control arm experienced ⩾ 1 serious AE (71.1 vs
64.3%), with febrile neutropenia (26.3 vs 14.3%), pneumonia (18.4
vs 9.5%), sepsis (7.9 vs 7.1%), thrombocytopenia (7.9 vs 7.1%),
sepsis during neutropenia (0 vs 7.1%), pyrexia (5.3 vs 0%) and
septic shock (5.3 vs 0%) being the most common serious AEs
reported in45% of patients in either arm. In the PAN+AZA arm, a
relative dose intensity of ⩾ 90% was achieved with PAN in only
47.4% of patients and with AZA in 71.1%. In the AZA arm, 73.8% of
patients had a relative dose intensity ⩾ 90%. A greater proportion
of patients in the PAN+AZA arm discontinued treatment due to
AEs (36.8 vs 23.8%). There were seven on-treatment deaths (PAN
+AZA, n= 5 (13.2%); AZA, n= 2 (4.8%)), all of which occurred
between cycles 1 and 3. None of the patients were known to be in
response. In the PAN+AZA arm, one patient died due to MDS and
two patients died due to causes that the investigator suspected to
be treatment-related (septic shock during grade 4 febrile
neutropenia and pulmonary hemorrhage during grade 4 throm-
bocytopenia). Neither of the deaths in the AZA arm was suspected
to be treatment-related.
Early efﬁcacy
Phase 1b. The clinical response rates were 33.0%, 33.0% and 42.9%
in the 20-, 30- and 40-mg cohorts, respectively.
Among patients with MDS/CMML across all dose cohorts, a
clinical response (CR, BM-CR, partial response (PR) or hematologic
improvement (HI)) was observed in six patients (30.0%; 95% CI,
11.9–54.3%), with 2 CRs (10.0%), 2 BM-CRs (10.0%), 1 PR (5.0%) and
1 HI (5.0%). Erythroid and platelet responses were observed in
3 patients (15.0%) each, and no patients had a neutrophil
response. Two patients relapsed following HI.
Five patients (45.5%; 95% CI, 16.7–76.6%) with AML showed a
clinical response (CR, CRi, PR), including 2 CRs (18.2%) and 3 CRi's
(27.3%). Treatment failure was observed in 3 patients (27.3%), and
best overall response was unknown in 3 patients (27.3%). One
patient with AML relapsed following CRi.
Phase 2b. A higher proportion of patients achieved a composite
CR in the PAN+AZA arm (27.5%; 95% CI, 14.6–43.9%) vs the AZA
arm (14.3%; 95% CI, 5.4–28.5%), including a slightly higher
proportion of patients achieving a CR (15.0 vs 9.5%) or achieving
a CRi or BM-CR (12.5 vs 4.8% (Table 5)). However, the overall
response rate (composite CR+PR+HI) was similar across the two
arms (PAN+AZA, 37.5%; AZA, 38.1%).
For patients with MDS/CMML, the composite CR rate was higher
in the PAN+AZA arm vs the control arm (29.0 vs 10.3%;
Supplementary Table 2). However, the clinical response (41.9 vs
41.4%), erythroid response (25.8 vs 31.0%), platelet response (35.5
vs 24.1%) and neutrophil response (19.4 vs 13.8%) rates were
similar across treatment arms. Relapse was reported in 22.6% of all
patients in the PAN+AZA arm vs 17.2% in the AZA arm. Among
patients with AML, the clinical response rate was 22.2% (95% CI,
2.8–60.0%) in the PAN+AZA arm and 30.8% (95% CI,
9.1–61.4%) in the control arm (Supplementary Table 3).
In the overall phase 2b population, the probability of being
progression free at 12 months, based on Kaplan −Meier analysis,
was similar for both treatment arms (PAN+AZA, 70% (95% CI,
40–90%); AZA, 70% (95% CI, 40–80%)). The 1-year survival rate,
as computed from the Kaplan −Meier analysis of OS, was 60%
(95% CI, 50–80%) in the PAN+AZA arm vs 70% (95% CI, 50–80%)
in the control arm (Figure 2).
Bone marrow aspirate samples from 37 patients (45.1%) were
collected for NGS, 20 from the PAN+AZA arm (7 achieved CR) and
Table 3. Frequent adverse events (⩾ 20%) regardless of study drug relationship by initial dose group of PAN in the phase 1b portion
PAN+AZA 20 mg (n= 6) PAN+AZA 30 mg (n= 18) PAN+AZA 40 mg (n=7) All patients (N= 31)
All grades,
n (%)
Grades 3/4,
n (%)
All grades,
n (%)
Grades 3/4,
n (%)
All grades,
n (%)
Grades 3/4,
n (%)
All grades,
n (%)
Grades 3/4,
n (%)
Nausea 4 (66.7) 0 14 (77.8) 3 (16.7) 7 (100.0) 1 (14.3) 25 (80.6) 4 (12.9)
Diarrhea 4 (66.7) 1 (16.7) 15 (83.3) 1 (5.6) 4 (57.1) 0 23 (74.2) 2 (6.5)
Fatigue 4 (66.7) 0 13 (72.2) 4 (22.2) 5 (71.4) 0 22 (71.0) 4 (12.9)
Thrombocytopenia 3 (50.0) 2 (33.3) 12 (66.7) 11 (61.1) 5 (71.4) 4 (57.1) 20 (64.5) 17 (54.8)
Vomiting 5 (83.3) 0 9 (50.0) 2 (11.1) 4 (57.1) 1 (14.3) 18 (58.1) 3 (9.7)
Constipation 2 (33.3) 0 11 (61.1) 1 (5.6) 3 (42.9) 0 16 (51.6) 1 (3.2)
Neutropenia 2 (33.3) 2 (33.3) 9 (50.0) 8 (44.4) 3 (42.9) 3 (42.9) 14 (45.2) 13 (41.9)
Decreased appetite 3 (50.0) 0 6 (33.3) 0 5 (71.4) 0 14 (45.2) 0
Anemia 2 (33.3) 1 (16.7) 8 (44.4) 6 (33.3) 3 (42.9) 3 (42.9) 13 (41.9) 10 (32.3)
Pyrexia 2 (33.3) 0 7 (38.9) 1 (5.6) 4 (57.1) 0 13 (41.9) 1 (3.2)
Hypokalemia 1 (16.7) 1 (16.7) 9 (50.0) 4 (22.2) 3 (42.9) 0 13 (41.9) 5 (16.1)
Asthenia 3 (50.0) 1 (16.7) 6 (33.3) 0 3 (42.9) 2 (28.6) 12 (38.7) 3 (9.7)
Hypocalcemia 3 (50.0) 0 7 (38.9) 1 (5.6) 1 (14.3) 0 11 (35.5) 1 (3.2)
Febrile neutropenia 2 (33.3) 2 (33.3) 6 (33.3) 5 (27.8) 2 (28.6) 2 (28.6) 10 (32.3) 9 (29.0)
Blood creatinine increased 1 (16.7) 0 5 (27.8) 0 4 (57.1) 1 (14.3) 10 (32.3) 1 (3.2)
Dyspnea 3 (50.0) 1 (16.7) 5 (27.8) 0 2 (28.6) 1 (14.3) 10 (32.3) 2 (6.5)
Abdominal pain 3 (50.0) 0 5 (27.8) 0 1 (14.3) 0 9 (29.0) 0
Peripheral edema 2 (33.3) 0 4 (22.2) 0 3 (42.9) 0 9 (29.0) 0
Abbreviations: AZA, azacitidine; PAN, panobinostat.
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17 from the AZA arm (0 achieved CR). The genes most often
mutated in the available samples include TP53 (51.4%), a tumor
suppressor gene; TET2 (29.7%), which promotes DNA methylation;
and RUNX1 (24.3%), a regulator of hematopoiesis (Figure 3).
However, there was no clear evidence of a relationship between
mutations and disease status or response.
DISCUSSION
In this study, the combination of PAN+AZA did not demonstrate a
substantial efﬁcacy beneﬁt compared with AZA alone in patients
with higher-risk MDS, CMML, and AML. Additionally, patients in
the PAN+AZA arm experienced a higher rate of grade 3/4 AEs.
Similar results were found in phase 2 studies of vorinostat+AZA for
higher-risk MDS and CMML,21 entinostat+AZA for MDS and AML,22
pracinostat+AZA for previously untreated MDS,23 and valproic
acid+decitabine for MDS and AML.24–26
However, these results were not anticipated for PAN+AZA
based on strong preclinical evidence supporting combined
treatment with PAN and demethylating agents13 and compelling
preliminary data from an uncontrolled phase 1b/2 trial examining
PAN+AZA in patients with higher-risk MDS and AML.27 Results
from that study by Tan et al. demonstrated an overall response
rate of 31% (9/29) in patients with AML and 50% (5/10) in patients
with high-risk MDS at the MTD of PAN 30 mg plus AZA 75 mg/m2.
Both the previous and present studies demonstrated better
clinical response in patients with MDS/CMML compared with AML.
In patients with AML, PAN did not enhance the clinical beneﬁt of
AZA. In patients with MDS/CMML, the composite CR rate was
nearly 3 times higher in the PAN+AZA arm (29.0% vs 10.3%). The
observed safety proﬁle in the previous study was similar to that
seen in the present study, with high rates of grade 3/4
hematologic AEs including neutropenia (96.2%), thrombocytope-
nia (91.7%) and anemia (88.9%).
Despite improvements in composite CR rates, particularly in
patients with MDS/CMML, there were no signiﬁcant improvements
in OS or time to progression with the addition of PAN to AZA
treatment in the present study. Although a number of factors
could have contributed to this outcome, the addition of PAN to
AZA is unlikely to positively impact therapy for patients with AML/
Table 4. Frequent adverse events (⩾15%) regardless of study drug relationship by treatment group in the phase 2b portion
PAN+AZA (n=38)a AZA (n= 42)a All patients (N= 80)
All grades, n (%) Grades 3/4, n (%) All grades, n (%) Grades 3/4, n (%) All grades, n (%) Grades 3/4, n (%)
Nausea 23 (60.5) 4 (10.5) 18 (42.9) 1 (2.4) 41 (51.3) 5 (6.3)
Thrombocytopenia 21 (55.3) 21 (55.3) 11 (26.2) 8 (19.0) 32 (40.0) 29 (36.3)
Diarrhea 19 (50.0) 3 (7.9) 9 (21.4) 1 (2.4) 28 (35.0) 4 (5.0)
Neutropenia 16 (42.1) 16 (42.1) 11 (26.2) 11 (26.2) 27 (33.8) 27 (33.8)
Vomiting 16 (42.1) 3 (7.9) 11 (26.2) 1 (2.4) 27 (33.8) 4 (5.0)
Pyrexia 19 (50.0) 2 (5.3) 8 (19.0) 1 (2.4) 27 (33.8) 3 (3.8)
Anemia 12 (31.6) 8 (21.1) 13 (31.0) 5 (11.9) 25 (31.3) 13 (16.3)
Constipation 10 (26.3) 2 (5.3) 15 (35.7) 0 25 (31.3) 2 (2.5)
Fatigue 8 (21.1) 2 (5.3) 16 (38.1) 0 24 (30.0) 2 (2.5)
Febrile neutropenia 13 (34.2) 12 (31.6) 8 (19.0) 8 (19.0) 21 (26.3) 20 (25.0)
Peripheral edema 8 (21.1) 0 8 (19.0) 0 16 (20.0) 0
Decreased appetite 10 (26.3) 2 (5.3) 6 (14.3) 0 16 (20.0) 2 (2.5)
Asthenia 8 (21.1) 1 (2.6) 6 (14.3) 0 14 (17.5) 1 (1.3)
Pneumonia 8 (21.1) 6 (15.8) 6 (14.3) 5 (11.9) 14 (17.5) 11 (13.8)
Headache 6 (15.8) 0 7 (16.7) 2 (4.8) 13 (16.3) 2 (2.5)
Epistaxis 6 (15.8) 1 (2.6) 6 (14.3) 0 12 (15.0) 1 (1.3)
Hypokalemia 6 (15.8) 4 (10.5) 6 (14.3) 1 (2.4) 12 (15.0) 5 (6.3)
Weight decreased 7 (18.4) 0 4 (9.5) 0 11 (13.8) 0
Cough 6 (15.8) 0 5 (11.9) 0 11 (13.8) 0
Platelet count decreased 7 (18.4) 5 (13.2) 2 (4.8) 2 (4.8) 9 (11.3) 7 (8.8)
Abdominal pain 6 (15.8) 1 (2.6) 1 (2.4) 0 7 (8.8) 1 (1.3)
Abbreviations: AZA, azacitidine; PAN, panobinostat. aTwo patients enrolled in the AZA arm did not receive medication. In addition, two patients enrolled in the
PAN+AZA arm received only AZA and were therefore included in the AZA group for analysis.
Table 5. Early efﬁcacy in the phase 2b portion
Best response PAN AZA AZA All patients (N= 82)
All
(n= 40)
MDS/CMML
(n=31)
AML
(n= 9)
All
(n= 42)
MDS/CMML
(n=29)
AML
(n= 13)
Composite CR, n (%)
(95% CI)
11 (27.5)
(14.6–43.9)
13 (41.9)
(24.5–60.9)
2 (22.2)
(2.8–60.0)
6 (14.3)
(5.4–28.5)
12 (41.4)
(23.5–61.1)
4 (30.8)
(9.1–61.4)
17 (20.7)
(12.6–31.1)
CR, n (%) 6 (15.0) 5 (16.1) 1 (11.1) 4 (9.5) 2 (6.9) 2 (15.4) 10 (12.2)
BM-CR (MDS/CMML) or CRi (AML), n (%) 5 (12.5) 4 (12.9) 1 (11.1) 2 (4.8) 1 (3.4) 1 (7.7) 7 (8.5)
Median time to progression (95% CI), months NE (11.1–NE) NA NA 15.2 (11.0–NE) NA NA NE (12.7–NE)
Median OS (95% CI), months 14.9 (10.4–NE) NA NA 15.6 (11.4–NE) NA NA 15.4 (13.0–NE)
Abbreviations: AML, acute myeloid leukemia; AZA, azacitidine; BM-CR, bone marrow complete response; CMML, chronic myelomonocytic leukemia;
CR, complete response; CRi, morphologic CR with incomplete blood count; MDS, myelodysplastic syndromes; NA, not analyzed; NE, not estimable; OS, overall
survival; PAN, panobinostat.
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MDS with the treatment schedule and in a clinical setting as
examined in this study. For example, patients may not have stayed
on treatment long enough to improve their OS; composite CR may
be a poor correlate to OS; the overall response rate, which was
similar between the two arms, may have a greater inﬂuence on OS
than composite CR; and the study may have been underpowered
for OS. It should be noted that the proportion of patients with
MDS/CMML achieving a PR or better response (17.2%) in the AZA
arm of the present study appeared lower than that in the AZA arm
(29%: 17% CR, 12% PR) of the pivotal phase 3 study of AZA vs
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conventional care in patients with MDS/CMML (AZA-001),6
potentially due to the rate of treatment discontinuation prior to
the ﬁrst efﬁcacy assessment at the end of cycle 2. Similarly, a
population-based analysis found shorter OS among patients
receiving AZA in clinical practice compared with those receiving
AZA-001.28 Another potential reason for the lack of survival
beneﬁt in the overall population could be the inherent difﬁculty in
selecting MDS/AML patient populations likely to derive beneﬁt.
Additionally, one limitation of the study is that there was no
central review or adjudication of responses.
Currently, there is no good universally accepted clinical
biomarker for response to epigenetic therapy in MDS/AML. The
study by Tan et al.27 demonstrated that an elevation of histone H3
and H4 levels of 450% from baseline following PAN treatment
strongly correlated with clinical response. However, a number of
other studies examining the correlation between acetylation levels
and response have failed to show an association, potentially due
to the use of less sensitive methodology.14,29,30 An additional
limitation of exploring histone acetylation levels as a potential
biomarker of response is that, while such markers are useful
universal pharmacodynamic markers of class I HDAC inhibition,
they do not measure the consequence of increased acetylation on
tumor cells (for example, at the gene expression or cell signaling
levels), and therefore cannot necessarily be expected to correlate
with response. There was no clear evidence of a relationship
between mutations and disease status or response. However, the
lack of data for patients in the AZA arm who achieved a CR and
the small sample size make it difﬁcult to draw conclusions.
Consideration should also be given to the potential role of the
sequence in which DACi and hypomethylating agents are
administered. Although this was reﬂected in scheduling the two
agents, with PAN started on day 3 of each cycle, both agents were
given concurrently for a substantial part of the ﬁrst week of each
cycle. Results from a phase 1 study showed that concurrent
administration of vorinostat and decitabine yielded better
responses compared with sequential administration;31 however,
PAN has been shown to induce cell cycle arrest,9 which may lead to
antagonistic effects when used in combination with AZA in the
present schedule. This concept is currently being evaluated in a trial
of concurrent vs sequential administration of entinostat and AZA
(NCT01305499). Thus, other doses and schedules of this or other
HDAC inhibitors in combination with AZA should be explored.
Furthermore, tolerability of PAN+AZA may have limited the
therapeutic efﬁcacy of this combination by preventing delivery of
sufﬁcient doses of PAN in particular. Only 47.4% of patients in the
combination arm received ⩾ 90% of the scheduled dose due to
dose reductions and interruptions, which were generally AE
related. This is one explanation provided for the lack of beneﬁt of
AZA plus vorinostat over AZA in the North American Intergroup
Study SWOG S1117.21 Hematologic toxicity is common to both
DACi and hypomethylating agents, so the potential for aggravat-
ing thrombocytopenia and neutropenia by combining these two
classes of drugs was anticipated when designing the study. Even
though we did not observe extremely prolonged cytopenia
attributable to study drugs, hematologic toxicity was the principal
reason for decreasing drug dose and interrupting or discontinuing
treatment. In contrast, gastrointestinal and constitutional AEs were
generally well managed and did not constitute a major manage-
ment problem during the DLT-deﬁning period, so that the number
of DLTs in all dose cohorts in phase 1b was below the threshold
for declaration of MTD. The overall long-term safety proﬁle of the
regimen in this study posed a challenge, with nearly all patients in
the PAN+AZA arm of phase 2b (97.3%) reporting ⩾ 1 grade 3/4 AE
vs 81.0% in the AZA arm. Common AEs (⩾ 50% in PAN+AZA arm)
were nausea, thrombocytopenia, diarrhea, and pyrexia, consistent
with the established safety proﬁle of both drugs as single agents
in patients with hematologic malignancies.6,10,32 Grade 3/4 AEs
were primarily managed through dose reduction/interruption,
leading to only moderate drug-related discontinuations. However,
the observed safety proﬁle was similar to AZA in combination with
other, less potent, DACi’s.14,29,33–36 Additionally, in phase 2b, there
was a higher rate of on-treatment mortality in the PAN+AZA arm
compared with the AZA arm, and the death of 2 of 5 patients in
the PAN+AZA arm was suspected by the investigator to be
treatment related. These results suggest that further dose and
schedule optimization is warranted to improve the tolerability of
the combination in this patient population. Studies have shown
that higher doses of AZA are associated with increased risk of
infection; thus, lower doses of AZA should be considered.37,38
The results of this study demonstrate that the regimen of PAN
30 mg plus AZA 75 mg/m2 has an unfavorable risk/beneﬁt proﬁle
in patients with MDS, CMML or AML, but also suggest that PAN
+AZA could provide clinical beneﬁt in select subsets of patients
(for example, patients with high-risk MDS). The development of a
consistent biomarker for patients with MDS/AML likely to respond
to DACi could help shift the risk/beneﬁt relationship. However, in
the current therapeutic landscape, further dose and schedule
optimization is warranted to improve the tolerability of the
combination in this patient population. It is worth noting that at
the time of data cutoff (30 April 2014), 3 patients from phase 1b
and 13 patients from phase 2b (PAN+AZA (n= 7); AZA (n= 6))
remained on treatment, with most patients having achieved CR.
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